Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 9:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Saxagliptin/Metformin, Fed Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin / Metformin Produc

NCT01441869
View directory record Official record
Conditions
Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin
Interventions
Onglyza (saxagliptin), Diabex, 5-mg saxagliptin/1000 mg metformin, 5-mg saxagliptin/500 mg metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Sep 23, 2026, 9:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants

NCT01068717
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state), Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state), Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state), Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2015 · Synced Sep 23, 2026, 9:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)

NCT00899470
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Co-administration of Saxagliptin and Metformin IR, Fasted, Saxagliptin/Metformin, Fasting, Co-administration of Saxagliptin and Metformin IR, Fed, Saxagliptin/Metformin, Fed
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
19 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 31, 2015 · Synced Sep 23, 2026, 9:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)

NCT01192139
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
saxagliptin, metformin XR, saxagliptin + metformin XR (FDC tablet)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Sep 23, 2026, 9:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR

NCT01192152
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
saxagliptin, Glucophage XR, saxagliptin + metformin XR (FDC tablet)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2015 · Synced Sep 23, 2026, 9:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

NCT03169959
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
2.5 mg Saxagliptin tablet, 5 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR, 5 mg saxagliptin, 10 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2017 · Synced Sep 23, 2026, 9:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)

NCT00897390
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Saxagliptin, Metformin IR (glucophage), Saxagliptin + Metformin IR (FDC)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
19 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Sep 23, 2026, 9:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study

NCT01874080
View directory record Official record
Conditions
Diabetes
Interventions
Saxagliptin/Metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Sep 23, 2026, 9:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered

NCT01068743
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
saxagliptin, metformin, saxagliptin + metformin (FDC tablet)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Sep 23, 2026, 9:00 PM EDT